Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which abnormal lymphocytes, most commonly B lymphocytes, accumulate in the blood, bone marrow, lymph nodes, and spleen. CLL usually develops slowly and may not cause symptoms early on.
The disease can affect the normal production and function of blood cells, potentially leading to anemia, increased susceptibility to infections, or low platelet counts. CLL is closely related to small lymphocytic lymphoma (SLL), with the distinction primarily based on where the abnormal lymphocytes are found.
A timely diagnosis helps determine the extent and biological characteristics of CLL and whether treatment is needed. Not every person diagnosed with CLL needs immediate treatment. Patients without symptoms or with stable disease may be managed with active surveillance, including regular blood tests and clinical assessments.
Causes
Risk Factors
CLL treatment has advanced with targeted therapies and molecular risk assessment, including BTK inhibitors and the BCL2 inhibitor venetoclax, which may be combined with anti-CD20 antibodies. Genetic and molecular testing, including TP53 abnormalities and IGHV mutation status, helps guide treatment selection, while newer options such as the non-covalent BTK inhibitor pirtobrutinib and cellular therapies expand treatment options for selected patients with relapsed or refractory CLL.
Active surveillance: Patients with early or asymptomatic CLL may be monitored regularly without immediate treatment.
Combination therapy: Targeted medicines may be combined with antibodies or other agents depending on the patient's disease characteristics.
Chemotherapy : Traditional chemotherapy has a more limited role than in the past but may still be considered in specific circumstances.
Cost Start From 300Explore Options
CAR-T Cell Therapy : It is specifically approved as a highly effective option for adults with relapsed or refractory CLL who have already exhausted standard BTK and BCL-2 inhibitor treatments.
Cost Start From 80000Explore Options
Stem cell transplantation : Allogeneic stem cell transplantation may be considered for a small number of carefully selected patients with high-risk, treatment-resistant disease.
Cost Start From 11500Explore Options
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Chronic Lymphocytic Leukemia (CLL) patients in India. These services include:









Rajkot, India
A leading multispecialty hospital in Rajkot, Wockhardt Hospital is committed to providing top-notch medical care and modern treatments. With a 95% satisfaction rating, Wockhardt has successfully treated 200,000 emergency cases and more than 1.4 million OPD patients. The hospital's dedication to providing high-quality care and safety is demonstrated by its NABH and NABL accreditation. Wockhardt guarantees easily accessible, high-quality healthcare by providing a surgery 0% interest-free EMI option and a fully furnished 'ICU on Wheels' that is open 24/7. Wockhardt Hospital is a reliable option for patients looking for advanced medical care in Rajkot and beyond because of its staff of skilled specialists and outstanding reputation for excellence.

Noida, India
Fortis Healthcare Limited is one of India’s prominent providers of integrated healthcare services, offering comprehensive medical care across multiple specialities. The company’s operations span hospitals, diagnostic centres, and day-care speciality facilities, ensuring a wide range of healthcare solutions under one umbrella. Fortis has established a strong presence across the country, managing 33 healthcare facilities, which include joint ventures and operational & management (O&M) setups, across 11 states.
The company’s hospital network comprises more than 5,700 operational beds, including O&M beds, catering to patients with varied healthcare needs. In addition to inpatient services, Fortis operates around 400 diagnostic laboratories, providing reliable and timely diagnostic support for accurate medical care. This extensive network enables Fortis to deliver high-quality healthcare services consistently and efficiently, from routine diagnostics to specialised treatments and complex procedures.

Delhi, India
Fortis La Femme, GK II, is a boutique multi-speciality hospital dedicated to women’s health, offering personalised and compassionate care. With 36 beds, it combines a patient-centric approach with an elegant, comfortable environment. The hospital provides a wide range of services, including Obstetrics with painless labour, Gynaecology and General Surgery using minimal access laparoscopic techniques, Fertility and IVF treatments, Neonatology with a Level III NICU, Onco Surgery for breast and gynaecological cancers, Cosmetology and Cosmetic Surgery, Endocrinology, Internal Medicine, Foetal Medicine, ENT, and Clinical Nutrition — all tailored to meet women’s unique healthcare needs.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome